Estimates for the prevalence of mutations in the general US population are 1/300 for Lynch syndrome and 1/400 for BRCA1/2, emphasizing that many mutation carriers remain undiagnosed [1–3]. This evidence concerns the gene BRCA1 and Lynch syndrome.